Detalles de la búsqueda
1.
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Lancet Oncol
; 22(4): 476-488, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33721561
2.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
N Engl J Med
; 375(8): 717-29, 2016 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27557300
3.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lancet Oncol
; 18(3): e143-e152, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28271869
4.
Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.
Br J Haematol
; 176(1): 65-75, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27766636
5.
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.
Breast Cancer Res Treat
; 155(3): 463-9, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26820652
6.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet
; 384(9938): 164-72, 2014 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24529560
7.
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Lancet Oncol
; 15(12): 1303-10, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25439688
8.
Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98.
Psychooncology
; 23(2): 173-82, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24038775
9.
Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting.
Eur J Cancer
; 197: 113496, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134481
10.
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.
JCO Precis Oncol
; 8: e2300687, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38635935
11.
Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial.
Lancet Oncol
; 13(4): 412-9, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22373563
12.
Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response.
Clin Cancer Res
; 29(1): 143-153, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36302172
13.
Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort.
Breast
; 71: 143-149, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37225592
14.
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.
Eur J Cancer
; 186: 52-61, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37030077
15.
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Lancet Oncol
; 12(6): 527-39, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21570352
16.
Imaging endpoints for clinical trial use: a RECIST perspective.
J Immunother Cancer
; 10(11)2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36424032
17.
Design issues in head and neck clinical trials: a statistician's perspective.
Anticancer Drugs
; 22(7): 682-7, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21709617
18.
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.
Ann Surg Oncol
; 17(7): 1854-61, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20300966
19.
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
Lancet Oncol
; 10(4): 341-50, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19246242
20.
Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.
Commun Biol
; 3(1): 397, 2020 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32719399